Article Text

Download PDFPDF

Response to: ‘Correspondence on ‘SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response’’ by Westhoff et al
Free
  1. Michael Bonelli,
  2. Daniel Aletaha
  1. Division of Rheumatology, Medical University of Vienna, Vienna, Austria
  1. Correspondence to Professor Daniel Aletaha, Department of Rheumatology, Medical University of Vienna, 1090 Wien, Austria; daniel.aletaha{at}meduniwien.ac.at

Statistics from Altmetric.com

We have read the correspondence of Westhoff et al to our article1 with great interest. The authors confirm our finding of an impaired humoral immune response in rituximab-treated patients by showing that also their rituximab treated patients did not develop antibodies to the SARS-CoV-2 spike protein after two doses of SARS-CoV-2 vaccinations with BNT162b2.2 In line with our data, the authors provide evidence for a maintained cellular immune response in rituximab-treated patients. In addition, Westhoff et al could quantify the presence of a CD4 and CD8 T cell response in 78% and 43% of the rituximab-treated patients, respectively. The finding of a dissociated humoral and cellular immune response is adding an important piece to the understanding of the scope of secondary immunodeficiency induced by rituximab. Nevertheless, this specific scientific field is strongly driven by questions about clinical relevance, and it remains not sufficiently clear what leg of the immune system is essential for successfully fighting a SARS-CoV-2 infection. However, to date, the clinical relevance of these findings remain elusive, as large vaccination studies with clinical endpoints for this patient population are challenging and quite unlikely, even in the currently very active research field.

For now, given the uncertainty on these details, the conclusion for patients on rituximab treatment can only be that vaccination is not without potentially protective effects, even if antibodies cannot be detected. Future studies would need to investigate what level of B cell repopulation is necessary to also achieve a humoral immune response to vaccination, and whether such response may be elicited, even in the absence of such repopulation, through an additional boost vaccination.

Ethics statements

References

Supplementary materials

Related Data

Footnotes

  • Handling editor Gerd-Rüdiger R Burmester

  • Contributors MB and DA drafted this response.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles